Abstract
7337 Background: Cyclooxigenase-2 (COX-2) is overexpressed in about 70% of NSCLC. Selective inhibitors of COX-2 have antitumor activity by blocking angiogenesis and apoptosis. The different mechanisms of action and the non-overlapping side effects suggest their association with cytotoxic agents. This Phase II study was designed to evaluate the activity and tolerability of weekly paclitaxel (PCT) plus celecoxib (CEL), and possible clinical correlations with biomarkers. Methods: PCT was administered at the dose of 80 mg/m2 IV weekly for six weeks followed by two-week rest, and CEL 400 mg p.o. bid continuously. A cycle consisted of 8 weeks. Serum/CTADplasma VEGF and IL-6 analysis was performed at baseline and every two cycles. Results: 53 patients (pts), previously treated with front-line platinum-based chemotherapy, entered the trial since January 2002. None of them had previously received taxanes. Pts characteristics: median (m) age 60 yrs (range 30–77); male/female= 43/10; PS 0/1/2= 31/20/2; 30 adenocarci...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
